What are the main indications for Anamorelin? Which types of patients and symptoms are suitable for

Anamorelin (Anamorelin) is an oral selective growth hormone secretion promoter, mainly used to treat weight loss and muscle wasting symptoms caused by cancer, especially in patients with cancer-related cachexia (cancer wasting disease). Cachexia refers to symptoms such as persistent weight loss, muscle atrophy, and decreased physical strength caused by long-term malignant diseases, usually accompanied by loss of appetite, weakness, and general malaise. Anamorelin helps improve patients' physical strength and muscle mass by promoting the secretion of growth hormone, thereby stimulating appetite and improving weight.

Anamorelin's primary indication is the treatment of cancer-induced cachexia, specifically symptoms such as loss of appetite, weight loss, and muscle wasting. Cachexia often occurs in some patients with advanced cancers, particularly those with digestive system-related cancers such as stomach, lung, colorectal, and pancreatic cancers. Cancer-related cachexia is an important factor leading to a decline in patients' quality of life. It not only increases the body's sense of weakness, but may also lead to a reduction in treatment efficacy and affect patients' treatment tolerance and survival.

Anamorelin is indicated for patients who have been diagnosed with cancer and are experiencing symptoms of cachexia, especially those with decreased appetite and weight loss caused by cancer treatment (such as chemotherapy or radiation therapy) or the cancer itself. This drug can help such patients regain their appetite, improve their weight, and relieve weakness and fatigue caused by muscle wasting.

Anamulin is suitable for patients with significant weight loss (more than 5%) accompanied by loss of appetite, muscle atrophy and decreased physical strength. In cancer treatment, the relief of cachexia symptoms can significantly improve the patient's overall quality of life, improve their tolerance to treatment, and may indirectly extend the patient's survival.

Anamorelin, as a drug that promotes appetite and improves body weight, is particularly suitable for patients with cachexia caused by cancer, helping to relieve cachexia symptoms and improve patients' quality of life. It has a good therapeutic effect on the symptoms of weight loss and muscle atrophy in cancer patients, and can help patients maintain a healthy weight and increase treatment tolerance.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/